Back

Selective reduction of left ventricular ejection time (LVET) in hypertrophic cardiomyopathy patients carrying mutations in MYBPC3

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 7 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Monica Patten

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

7 More presentations in this session

Presentation thumbnail
Identification of a novel actin gene mutation, ACTC1 p.Asn94Ile, in a family with cardiomyopathy and conduction disease
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Refining the diagnosis of hypertrophic cardiomyopathy with a machine learning-based radiomics model: a cardiovascular magnetic resonance study
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Different exercise hemodynamic profiles in obstructive and nonobstructive hypertrophic cardiomyopathy: importance of unmasking diastolic dysfunction
Doctor C. Baratto (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance feature tracking identifies preclinical abnormalities in hypertrophic cardiomyopathy sarcomere gene mutation carriers
Doctor F. Negri (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Unraveling the complexity of hypertrophic cardiomyopathy: a machine learning-based radiomics model to predict phenotype and cardiovascular events
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Clinical profile and outcomes of patients with hypertrophic cardiomyopathy associated with mutations in the MYH7 gene: a long longitudinal follow up study
thumbnail
Congress Presentation
The relationship between the presence of genetic mutations and left atrial function in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources